 Bolts first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 78 immune-stimulating antibody conjugate ISAC currently in an ongoing Phase 12 first-in-human study Bolts first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 78 immune-stimulating antibody conjugate ISAC currently in an ongoing Phase 12 first-in-human study 